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INTRODUCTION
Many of the papers presented at this symposium will demonstrate that
certain biological mechanisms or processes are theoretically able to affect
the yield of radiation-induced cancers in vivo, but undoubtedly there will
be opposing views regarding their actual importance. This stems, at least
in part, from the fact that no two test systems used to assess the importance
of a given mechanism are exactly alike, and different results are therefore
to be expected. The point we wish to make in the present report is that it
is not necessary to compare different test systems in order to generate a
conflict, since it is possible to obtain diametrically opposed evaluations
regarding the importance of a given mechanism merely by altering the region
of the dose response curve studied.
In specific terms, our proposal states that the relative importance of
each biological mechanism will vary as a function of the total dose or dose
rate, because these two variables affect not only the extent but also the
nature of the injury induced in target and non-target cells, alike. In a
sense this proposal is not new since it follows quite logically from a
variety of predictions obtained in the study of dose response curves (1).
What little originality exists stems from the combination of these predic-
tions with biologically observable phenomena. If this proposal is valid,
its value lies not only in resolving certain of the conflicts in the lit-
erature, but also in providing a rational means of predicting the carcino-
genic hazards associated with radiation exposure conditions which cannot
be simulated in the laboratory.
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A priori, there are a number of cases in which support for our pro-
posal is self-evident: low radiation doses (<£l00 rads), which are at best
marginally immunosuppressive (2) do not compromise the hosts ability to
cope with oncogenic virus or tumor cell antigens, while higher doses do
(3); fractionation or protraction of a radiation dose can either increase
or decrease the cancer yield, depending on the region of the dose-response
curve studied (4,5); and low doses of radiation can produce "negative injury"
as evidenced by prolongation of the lifespan of the exposed animals (6).
Vie concern ourselves here, not with these aspects, but with two more subtle
problems which have been the subject of debate in recent years: the dependence
of recovery from radiation carcinogenic injury on dnse size, and the role of
immunosuppression versus target cell disturbances in radiation leukemogenesis.
RECOVERY FROM RADIATION CARCINOGENIC INJURY AS A FUNCTION OF DOSE SIZE
The dose-response curves for low linear energy transfer (LET) induction
of cancers are, at least theoretically (7) composed of three regions: the
low dose region in which tumor yield increases linearly with dose; the inter-
mediate region in which tumor yiald increases as a^l power of the dose;
and the high dose region in which the cell killing effects more than counter-
balance the increased number of transformations and tumor yield declines
progressively. The radiation doses which delimit these regions vary as a
function of the tumor type in question (see below), but in most instances
it is not possible to differentiate between the low and intermediate regions
of the curve, i.e., the low dose region is small relative to the dose
levels normally employed. We will use the terms low and linear interchangably;
this also holds true for the terms intermediate and curvilinear.
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In the absence of a system which would allow differentiation of the low
from the intermediate dose region, few of the questions relating to the role
of dose size in radiation recovery' from carcinogenic injury could be addressed.
A number of test systems were studied in an attempt to develop one for this
analysis, and the most useful of these was the radiation induction of benign
lung adenomas in the RF mouse (8). The unique features of this test system -
include: negligible mortality between treatment and analysis ; constant
tumor yields between 6 and 12 months after treatment; and the develop-
ment of multiple tumors in individual animals, thereby allowing use of "mean
number of tumors per mouse" as the response endpoint, as opposed to the more
erratic incidence data(3).
In our pilot studies, a dose range of 750 to 3000 rads of localized
thoracic 250 kVp X-rays were studied (8). Two points were established in
these experiments: that the dose-response curve between 750 and 1500 rads
was curvilinear, and that 1500 ^ads was the upper limit of the intermediate
dose region. In order to determine whether the theoretically predicted linear
component would be observed, we expanded these studies to include localized
doses of as low as 250 rads. Figure 1 is a plot of the mean number of induced
adenomas (treated mean minus control mean) per mouse observed 7 to 11 months
after localized thoracic doses of 250 to 1500 rads. Between 250 and 750 rads,
the slope of the log-log plot of response on dose is not significantly dif-
ferent from 1, indicating that the induction of benign adenomas in this dose
range is a simple linear function. At the higher doses (750 to 1500 rads), the
log-log slope of response on dose is significantly greater than 1 (P<..01)
suggesting that an interaction between events is contributing to tumor yield.
For comparison, we have included data on similar mice given graded doses of
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urethane (ethyl carbamate) instead of localized X-rays. The shape of the
overall dose-response curve for this chemical carcinogen is essentially
identical to that for the localized X-rays: 125 to 500 mg of urethane per
kilogram of body weight defines the linear portion of the dose-response
curve, while higher doses are described by a curve which has a log-log
slope of>l (P < .001)(Figure 1).
The important point for the present discussion is not the specific
doses which define the transition from a linear response to a curvilinear
one, but rather the implications these two areas of the curve have for the
process of recovery. For the case of the localized X-rays, at least, the
linear relationship between dose and response (Figure 1; 250 to 750 rads)
indicates that a single ionizing event is responsible for tumor induction
in this dose range. In the higher dose region, where the log-log slope is
significantly greater than 1 (Figure 1; 750 to 1500 rads) an additional
mechanism appears to be contributing to the yield of tumors, namely, the
interaction of ionizations, each of which alone was unable to produce a
tumor. A carcinogenic process which requires only a single ionization
should be independent of the rate of carcinogen administration, whereas,
if more than one ionization is required, a slow rate of administration
might allow recovery of the initial injury before additional ionizations
occur. In other words, there should be no recovery from total doses which
fall on the linear portion of the dose response curve, but there should be
significant recovery from total doses which fall on the curvilinear portion
of the curve, when the doses are given over a prolonged period of time as
opposed to acute administration.
In order to test this prediction of the dose-response curve (Figure 1),
we chose the highest total X-ray doses which fell on the linear portion of
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the dose response curve (750 rads) and on the curvilinear portion of the
same (1500 rads) and administered them either as a single dose or as two
equal fractions separated by 24 hours. If no recovery oee-ured during the
24 hour fractionation interval, then the tumor yield should be the same
in the single and split dose groups. If "recovery from the first dose
equalled 100%, then the tumor yield in the split dose group should equal
that of mice given only one of the two fractions (i.e., half of the total
dose). The theoretical predictions of the dose-response curves were con-
firmed quite clearly, in that highly significant recovery was observed
in the group given two fractions which totalled a dose which fell on the
curvilinear portion of the dose response curve, 1500 rads (Table 1),
while no recovery was apparent when a dose which fell on the linear portion
of the curve (750 rads) was fractionated (Table 1).
Similar fractionation experiments were performed with urethane, since
it showed a single dose-response curve similar to that of localized X-rays
(Figure 1). Table 2 summarizes the results of an experiment in which we
fractionated urethane doses which fell either on the linear (500 mg/kg)
or curvilinear (1000 mg/kg) portions of the dose response curve. Again,
the same pattern was observed (Table 2): significant recovery was observed
when a total dose within the curvilinear range was fractionated (P<0.02),
bu no recovery was apparent when a single dose on the linear portion of
the curve was fractionated. Extension of the recovery interval from
24 to 96 hours (Table 2) failed to allow the demonstration of recovery in
the low total dose group, and, in fact, apparent "negative recovery" was
observed. It should be noted that urethane data similar to that presented
above (Figure 1 and Table 2) has been published elsewhere (9,10) and ex-
tension of our analysis to it leads to essentially the same conclusions.
For the localized X-rays, we propose that the single events which are
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contributing to tumor yield in the linear range, and the single and multiple
events which are contributing to tumor yield in the curvilinear range are
ioninations within the target cells of the irradiated lung. In brief, v.-e
propose that our results are compatible with the predictions of the dual
action theory of radiation injury (7). The urethane data, although showing
similar kinetics, need not be the product of identical or even similar
processes. Urethane was administered systemically, and it is possible that
the event interaction in the curvilinear portion of the dose-reaponse
curve (Figure 1) reflects the development of significant irraunosuppression
(11) or prolonged retention time of the carcinogen (I2)which does not occur in
the low dose region. Immunosuppression would appear to be an unlikely
candidate for this additional event, since the adenomas are very weakly
immunogenic, and mice treated with 1000 mg/kg of urethane are no more or
less resistant to transplants of this tumor (13). Although unlikely, due
to the time factors involved, a prolonged carcinogen retention time remains
a possible interpretation.
Whether or not the event interaction involved in the two carcinogenic
mechanisms is the same, it is interesting to note that recovery is dose
dependent in both cases. However, at equally carcinogenic doses (e.g., a
mean of 1 induced adenoma per mouse) one is well into the X-ray dose range
in which recovery would occur (Figure 1 ) , but is still well within the
"no recovery" dose range for urethane. Therefore, protraction of this X-ray
dose would produce significantly fewer tumors, while protraction of the
1 - The author acknowledges these suggestions by Profs. N. Haran-Ghera and
J. Neyman, respectively.
. - . . - : • . ^ - .
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urethane dose would produce as many tumors as the same total dose given
acutely. We suggest that information such as this may prove to be more
valuable to those estimating comparative hazards than simple estimates of
carcinogenic efficiency.
As a last point, it must be emphasized that the radiation doses which
define the break between the linear, "no recovery" portion of the dose-response
curve and the curvilinear portion are heavily dependent on the tumor being
studied. As an example, in the ovarian tumor system, recovery is constant
between doses of 49 and 392 rads (14), In this highly radiosensitive system,
we have been unable, as yet, to detect the linear portion of the dose-response
curve. We concur,therefore, with the reccomendations of the Aspen report (15),
which suggested that the definition of the low dose range is dependent on
the test system employed, and that for each it is that region in which the
effect is linearly proportional to dose.
ACUTE AHD CHRONIC RADIATION EFFECTS ON RESISTANCE TO QNCOSEMIC VIRUSES
For a number of years, it has been known that administration of 600 to
700 rads as four equal weekly fractions was far more leukemogenic than the
administration of the same total dose acutely (16), at least in the C57BL
mouse. This repeatedly observed phenomenon stands in contrast to what might
be expected if significant recovery from immunosuppression occured or if
recovery from carcinogenic injury occured in the fractionally exposed group.
It has been suggested,therefore, that fractionation proves to be more leuk-
emogenic because these e> ,sures disturb the normal target cell kinetics
thereby placing more of them in a sensitive state (17). The exact nature of
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this disturbance is not clear, but recent evidence provided by Tennant (13)
has demonstrated that actively dividing cells are more susceptible to radia-
tion activation of endogenous leukemia viruses, and that chronic irradiation
is more effective in this regard than is acute irradiation, even after cell
survival is taken into account.
At the risk of over-generalizing, we propose that radiation can increase
the leukenia incidence either by inducing such a heavy viral burden that im-
mune responsiveness is irrelevant, or by suppressing immune responsiveness
such that even snail viral burdens can prove to be significant. In additic
to being a means of reconciling the opposing views in this argument, this
proposal is consistent with established patterns: those exposure regimens,
such as fractionated or chronic exposures, which are highly leukemogenic
in spite of their weak immunosuppressive capabilities, are highly efficient
in activating endogenous leukemia viruses (18); and, conversely, those exposure
regimens, such as acute exposures, which are moderately leukemogenic in
spite of their weak virus activation capabilities (18,19), are strongly im-
munosuppressive (3). Consistency alone cannot prove or disprove a proposal,
so v/e have initiated a series of experiments designed to test this proposal,
and present below the results of these initial investigations.
For the host in these studies v/e have used adult (4-month-old) BALB/c
females, v/hich are essentially insensitive to the induction of leukemia by
either acute or chronic gamma rays over a wide range of doses and dose rates
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(13,14). Groups of these mice (N=16) were exposed to 392 rads of Cs
gamma rays at dose rates of 41 rads/min (ACUTE) or 28 rads per day (CHRONIC).
Following exposure^these mice, along with unirradiated controls, were allowed
to recover through the age of 6-months, at which time all mice were given
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an intramuscular injection of 0.1 ml of the Moloney strain of the murinc
leukemia/sarcoma virus complex, henceforth referred to as MSV/MLV. Since
our intent in these studies was to study the development of leukemia, we
passaged our original low-leukemia line of this virus (20) through two
in vivo passages, and thereby increased its leukemogenic potency (see
be!ow).
This experiment is still in progress but the
data obtained to date are more than sufficient to answer the question
posed by these studies. It should be noted that unirradiated and irradiated
(ACUTE or CHRONIC) mice demonstrated less than 7% mortality within the
first 8 months of the experiment in the absence of MSV/MLV injection.
Figure 2 is a plot of the percent mortality versus time for the virus
injected control and irradiated mice. Control mice began to die between
90 and 100 days after virus injection, but this wave of deaths completed
by the 160th day after injection, with negligible further mortality through
the 230th day. Radiation exposure of the mice prior to the virus injection
altered the mortality pattern, but the direction of its alteration depended
on the manner in which the 392 rads was applied (Figure 2). Mice given 392
rads at 28 rads per day (Figure 2; CHRONIC) began to die between days 70 and
80 of the experiment, and all had died by the 160th day post-virus-injection.
Conversely, mice given 392 rads in a matter of minutes (Figure 2; ACUTE)
did not start to die until the 110-li'O day interval, and then only gradually,
but significant mortality was observed between days 160 and 230 of the
experiment. The apparent explanation for these anomalous patterns can be
seen in the analysis of the causes of death in these mice. Typical MSV/MLV
induced leukemias occured exclusiveTy-within the first 160 days after virus
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injection while none of the sr.rr.om^ s wlrirfr rfov^oped rccured L ^ c e the 140th
day after inject1'on. This latter observation confirms our earlier estimates
on the rate of development of sarcomas under similar conditions (21). Table
3 summarizes the probabilities of dying of leukemia during the early period
(through day 160} and of dying of a sarcoma during the later period (day 140
through 230) for each of the experimental groups. Relative to unirradiated
mice, chronic irradiation increased the probability of developing leukemia,
and acute irradiation suppressed it, and both of these alterations are statis-
tically significant (Table 2). No valid estimate of the probability of dying
with a sarcoma is available for the chronically irradiated group, but acute
irradiation induced an increase in the risk of sarcoma relative to unirradiated
mice. At the time of writing (day 230 of the experiment) the difference in
risk of dying with sarcoma between the control and acutely irradiated group
was not statistically significant (P<0.10). It should be remembered, however,
that almost all of these mice will eventually develop an injection site sar-
coma (21), with the acutely irradiated group demonstrating a much faster rate
of development (see above and 21). In support of our prediction regarding the
eventual fate of the control and acutely irradiated mice still alive at day
230 of the experiment stands the observation that none of the control mice
possessed palpable injection site tumors on day 230 (0/6), while almost all
of the acutely irradiated mice did (7/9). We conclude.therefore, that exposure
of mice to chronic gamma rays prior to a large virus challenge sensitizes them
to the development of leukemia, while acute pre-exposure makes them resistant
to leukemia but sensitive to sarcoma induction.
Our proposal was that immunosuppression would only be important in the
development of radiation induced leukemia if the viral burden were low, but
that disturbances in the target cell kinetics could more than counterbalance
any lack of immunosuppression either by providing a source of sensitive cells
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in which the virus can accomplish transformation or by placing the target cells
in a sensitive stage for activation of endogenous viruses (18). The data
presented above have provided only a partial test of this proposal, in that
we have standardized for the amount of virus present (by adding it exogenously)
and determined the role of chronic versus acute exposure in altering sensitivity
to the virus. Quite clearly, one cannot argue that immunosuppression is
responsible for the radiation induced alterations in sensitivity to the exogenous
virus. What appears more likely is that chronic irradiation enhances the
sensitivity of the target population either quantitatively (more cells at risk)
or qualitatively (more rapid cycle times), while acute irradiation depletes
or at least reduces the size of the target population. We are at present testing
these points directly. Preliminary results suggest that the chronic radiation
induced sensitization to leukemia declines as the time between completion of
exposure and virus injection increases. Conversely, the acute irradiation effect
does not alter appreciably as the interval between the two is increased. These
observations are consistent with our proposal. -
An interesting point observed in these studies is that although acute
irradiation elevates resistance to the leukemogenic effect of MSV/MLV, it
apparently sensitizes to the sarcomagenic effects of the same. (Table 3).
Undoubtedly, this is related to the fact that the target and effector cells
in virus induced leukemia are one in the same, while in sarcomagenesis, they
are quite distinct. Therefore, in the development of sarcomas, depletion of
the lymphoid tissue can only serve to reduce the hosts resistance to the
development of tumors from muscle cells.
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We are currently testing the second aspect of our proposal, i.e., that
immunosuppression can prove to be important in radiation leukemogenesis when
the viral burden is low. The results are too preliminary to warrant discussion,
but they are not inconsistent with the argument that the immune system is
able to cope with only limited tumor burdens (or viral burdens), and that
their importance is restricted to a very limited range of experimental con-
ditions (22).
SUMMARY
In the data presented above, we have demonstrated that at least three
types of mechanisms can contribute to the yield of radiation induced cancers,
but that the relative contribution of each depends heavily on the exposure
conditions, and on the tumor type in question. A continued consideration of
the mechanisms involved relative to the dose response curves observed would
appear to be the most fruitful approach to the study of the biology of radiati
carcinogenesis.
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Table 1. Recovery from radiation carcinogenic injury to the mouse lung
as a function of dose s ize . The exposures were given either
as a single dose or as two equal fractions separated by 24 hours.
Exposure Method
Single Dose
Single Dose
Two Fractions0
Single Dose
Single Dose
Two Fractions0
Total
Radiation
Dose
(rads)
1500
750
1500
750
375
750
Number
of Mice
27
29
24
29
21
28
Induced Lunga
Adenomas
(mean +_ s.e.)
1.56 +_0.21
0.38 +_0.09
0.96 +0 .19
0.38 +0 .09
0.09 + 0.04
0.49 +0 .06
Recovery
-
51
_
-
-38
a - mean observed in the irradiated group minus the control mean of 0.39
adenomas per mouse.
b - 100% recovery equals a mean number of induced adenomas identical with
that observed in mice given only half of the total radiation dose, i . e . ,
750 rads and 375 rads, respectively,
c - two equal fractions given at a 24 hour interval.
Table 2. Recovery from urethane-induced carcinogenic injury to the mouse lung
as a function of dose size. The injections were given either as
a single dose or as two equal fractions separated by 24 to 96 hours.
Injection
Method
Single Dose
Single Dose
Two Fractions
Single Dose
Single Dose
Two Fractions
Two Fractions
Two Fractions
Total
Urethane
Dose
(ing/kg)
1000
500
C
 1000
500
250
C
 500
c
 500
C
 500
Time
Between
Fractions
(hrs)
-
24
-
-
24
48
96
Number
of Mice
31
36
32
36
35
31
31
30
Induced Lunga
Adenomas
(mean +_ s.e.)
16.64 +_0.89
4.12 +0.39
8.73 +0.91
4.12 +_0.39
2.13 +0.26
3.97 +0.39
4.56 +_ 0.35
5.52 +0.39
Recovery
(%)
-
63
-
7
-22
-70
a - mean observed in the treated group minus the control mean of 0.43
adenomas per mouse.
b - 100% recovery equals a mean number of induced adenomas identical with
that observed in mice given only half the total urethane dose, i.e.,
500 mg/kg and 250 mg/kg, respectively.
c - two equal fractions given at the specified intervals.
Table 3. Deaths attributable to leukemia and sarcoma in control and pre-irradiated
mice given MSV/MLV^ through the first 230 days of the experiment.
Pre-irradiation Leukemia Deaths Sarcoma Deathse
Controls 9/16 l/7f
Chronically Exposedb 16/I6h
Acutely Exposed0 2/161 5/14g
a - MSV/MLV given intramuscularly at the age of 6-months; this equals day 0
of the experiment.
b - given 392 rads at 28 rads per day starting at 4-months.
c - given 392 rads at 41 rads/min at the age of 4-months.
d - cause of death disseminated leukemia; no sarcomas detected, except in one
on the two Acutely exposed mice.
e - deaths due to local and metastatic sarcoma deposits,
f - none of the 6 mice surviving to 230 days possessed palpable sarcomas
g - 7 of the 9 mice surviving to 230 days had palpable sarcomas,
h - significantly greater than respective value in controls (P< .005) and
in acutely exposed (P <.0005)
i - significantly smaller than respective value in controls (P<.01) and
chronically exposed (P<.0005).
FIGURE LEGENDS
Figure 1. Mean number of papillary lung adenomas per mouse induced by graded
doses of urethane or localized X-rays. Induced values corrected for
spontaneous control value (0.39 to 0.43 adenomas per mouse). Numbers
on each of the curves represent the maximum liklihood estimates of
the log-log slope.
Figure 2. Percent mortality as a function of time in BALB/c mice given MSV/MLV
at the age of 6-months. Time zero on the plot coincides with the time
of virus injection. CONTROLS received no irradiated prior to the virus;
the CHRONIC RADIATION group received 392 rads of gamma rays at a rate
of 28 rads per day starting at the age of 4-months (exposure time =
14 days); and ACUTE RADIATION group received 392 rads of gamma rays
at 41 rads per min at the age of 4-months.
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